Eculizumab in kidney diseases
The C5 inhibitor monoclonal antibody, eculizumab, has been approved for the treatment of atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH); however, the efficacy and safety of this drug in treating other complement-related renal diseases has not yet been elucida...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Bog |
| Udgivet: |
Society of Diabetic Nephropathy Prevention,
2024-01-01T00:00:00Z.
|
| Fag: | |
| Online adgang: | Connect to this object online. |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|
Internet
Connect to this object online.3rd Floor Main Library
| Klassifikationsnummer: |
A1234.567 |
|---|---|
| Kopi 1 | Tilgængelig |